PubMed Health⌕ Search

Biomedical subjects

V Quiñones-Jenab

Publications and source records attributed to V Quiñones-Jenab.

18 recordsLinked to original sources

Gonadal hormones differentially modulate cocaine-induced conditioned place preference in male and female rats.

There is accumulating evidence that suggests there are sex differences in behavioral and subjective responses to cocaine. However, it is not known whether differences in cocaine reward contribute to sex differences in these responses or whether gonadal hormones affect the rewarding properties of cocaine. In the present study, conditioned place preference (CPP), a measure of non-contingent reward, was used to determine the effects of endogenous gonadal hormones and of estrogen and progesterone replacement on cocaine reward. Neurochemical measurements were also taken to identify monoaminergic substrates which underlie the behavioral phenotype. Although both intact and gonadectomized male and female rats showed a significant CPP for cocaine, ovariectomy attenuated the magnitude of CPP. These alterations coincided with a decrease in serum levels of corticosterone. In ovariectomized rats, pretreatment with progesterone inhibited cocaine CPP while estrogen plus progesterone potentiated the magnitude of CPP. Additionally, gonadectomy and ovarian hormone replacement in female rats affected serotonin/dopamine levels and turnover ratios in the ventral tegmental area and nucleus accumbens shell. While no effects of castration were observed, ovariectomy decreased levels of dopamine and serotonin in the ventral tegmental area. In females, progesterone replacement increased levels of serotonin and dopamine in the ventral tegmental area, while estrogen plus progesterone replacement increased dopamine levels in the nucleus accumbens. Collectively, these results indicate that ovarian hormones may influence cocaine reward by altering monoaminergic systems, which, in turn, may contribute to the current sex disparities in overall cocaine use.

Analysis of Variance↗

Temporal effects of estrogen and progesterone on behavioral and endocrinological responses to acute cocaine administration.

Estrogen and progesterone have been postulated to play a key role modulating cocaine-induced behavioral and neurochemical activation in female rats. This study investigated the temporal relationship between estrogen and progesterone in the modulation of cocaine-induced behavioral alterations. Ovariectomized Fischer rats received s.c. injections of estradiol benzoate 48 hr prior to cocaine or saline treatment and one s.c. injection of progesterone concurrently or 1, 4, 20, 24, 30, 44 or 48 hr after estrogen treatment. Forty-eight hours after estrogen treatment rats received either a single i.p. injection of 15 mg/kg of cocaine or 0.9% saline. Overall, cocaine induced increases in locomotor behaviors (ambulatory and rearing activity). A bimodal interaction between estrogen and progesterone was observed in the modulation of all locomotor activities. A gradual increase in behaviors, which peaked when progesterone was administered 24 hr after estrogen was followed by an inhibition of both ambulatory and rearing activity when progesterone was administered for a shorter period of time. This estrogen and progesterone interaction was not observed in the modulation of cocaine-induced stereotypic activity. However, shorter administration of progesterone in relation to estrogen administration resulted in lowered benzoylecgonine plasma levels when compared to longer progesterone administration times. On the other hand, longer administration of progesterone (48 hr of estrogen and progesterone) caused increases in corticosterone levels in cocaine-treated rats. Thus, the temporal interaction between estrogen and progesterone in the regulation of cocaine metabolism and hypothalamic-pituitary-axis (HPA) activation do not completely correlate with that observed for locomotor behavioral activation. Taken together, these results suggest that temporal interactions between estrogen and progesterone may underlie some of the previously reported estrous cycle and sex effects on cocaine-induced behavioral and endocrinological alteration.

Acute Disease↗

Vendor differences in cocaine-induced behavioral activity and hormonal interactions in ovariectomized Fischer rats.

Contradictory effects of ovarian hormone on cocaine-induced behaviors have been reported in ovariectomized Fischer rats. To determine if these discrepancies are based on where the rats were purchased, Charles River Laboratories and Taconic Fischer rats were randomly assigned to either cocaine (15 mg/kg, intraperitoneal) or saline treatment; and one of four hormone-pretreatment subgroups: vehicle, estrogen, progesterone or estrogen + progesterone. Vendor differences were observed in cocaine-induced locomotor activities; overall, Taconic rats demonstrated less locomotor activity than Charles River rats. Furthermore, vendor differences in ambulatory activity were also observed after steroid replacement treatment. In Charles River rats, estrogen + progesterone co-administration suppressed cocaine-induced increases in ambulatory activity when compared to other hormone-treated groups given cocaine. In contrast, Taconic rats showed an increase in ambulations after this drug/hormone treatment. Vendor differences were also observed in steroid effects on cocaine-induced rearing activity, where estrogen + progesterone and cocaine caused an increase in rearing in Charles River rats, but not in Taconic rats. No differences between the vendors were observed in saline- or cocaine-treated animals' stereotypic activity. Vendor differences in cocaine-induced locomotor activity were not due to differences in cocaine metabolism, as no differences in plasma levels of benzoylecgonine were observed. Interestingly, Taconic animals had overall higher plasma levels of corticosterone than Charles River rats. Thus, intrinsic differences between different lines of Fischer rats may affect the outcome of ovarian hormone interactions in cocaine-induced behavioral alterations.

Animals↗

Endocrinological basis of sex differences in cocaine-induced behavioral responses.

Currently, 1.8 million Americans use cocaine, 30% of whom are females. Sex differences in the pattern of cocaine abuse may reside in neuroendocrinological modulations that affect the use of and/or dependence on cocaine. This review discusses sex differences in cocaine-induced behavioral and molecular alterations in the central nervous system, with emphasis on the role of endocrine responses in the neuronal modulations of this drug. Mechanisms and data supporting the role of the hypothalamic-gonadal axis in the modulation of cocaine-induced behavioral and molecular alterations are also provided.

Animals↗

Ovarian hormones modulate cocaine-induced locomotor and stereotypic activity.

Interactions between ovarian hormones and cocaine may underlie gender and estrous cycle differences in cocaine-induced behavioral and neurochemical alterations. The aim of this study was to further understand how ovarian hormones modulate cocaine-induced behavioral alterations. Ovariectomized rats received acute or chronic saline or cocaine (15 mg/kg i.p.) administration and were further subdivided into one of four hormone-treatment conditions: cholesterol (vehicle-control), estrogen, progesterone, or estrogen + progesterone. Overall, acute and chronic cocaine administration increased all locomotor measurements (total locomotor, ambulatory, and rearing counts). Estrogen administration augmented cocaine-induced increases in ambulatory and rearing activity. After chronic cocaine administration, rats in the vehicle-control group developed behavioral tolerance (exhibited by a decrease in activity) in rearing and ambulatory activity. Estrogen replacement not only prevented the development of tolerance in ambulatory and rearing activities, but also enhanced total locomotor activity (sensitization) in response to chronic cocaine. Progesterone treatment did not alter the behavioral responses to acute or chronic cocaine administration. Estrogen + progesterone-treated animals had higher counts of locomotor activity in response to chronic cocaine than did vehicle-control or progesterone-treated rats. In stereotypic behaviors, the different hormonal treatments did not affect activity in cocaine- or saline-treated rats after acute or chronic drug administration. Plasma levels of cocaine did not change after different hormonal treatments. Interestingly, animals' coadministered chronic cocaine and estrogen had higher levels of corticosterone than did nonestrogen cocaine-treated rats. Thus, it is likely that alterations in HPA activation may underlie the observed behavioral differences. In summary, these data suggest that there are interactions between ovarian hormones and cocaine-induced behavioral alterations in female rats, and they extend previous results by showing that estrogen and progesterone affect the development of sensitization.

Animals↗

Sex differences in cocaine-induced behavioral sensitization.

To further understand how sex differences affect the development and maintenance of sensitization, 48 adult Fischer rats (24 female and 24 male) received chronic administration (14 days) of cocaine (15 mg/kg, i.p.) or saline or a challenge dose (7 days after chronic cocaine administration). Sex differences were observed in the development and maintenance of cocaine-induced total locomotor, ambulatory and rearing activity. Although, overall cocaine administration increased stereotypic activity in both male and female rats, female rats had significantly higher stereotypic activity than male rats across the three behavioral test days (1, 7 and 14). Female rats had statistically significant higher benzoylecognine levels after acute cocaine administration than male rats. However, no differences between male and female rats in benzoylecognine plasma levels were observed after chronic and challenge doses of cocaine administration. Interestingly, after acute and challenge cocaine administration, corticosterone levels were significantly higher in female rats when compared to male rats. This study confirms previous reports that there are sex differences in the behavioral response to cocaine. Moreover, this study expands previous studies by demonstrating that sex differences occur in only certain aspects of cocaine-induced behavioral activation and the development and maintenance of cocaine-induced behavioral sensitization.

Animals↗

Chronic 'binge' pattern cocaine alters the neuroendocrine profile of pregnant rats.

Pregnant Fischer rats injected with cocaine in a 'binge' pattern (3x15 mg/kg, i.p.) from gestational days 8 through 17, had significantly higher levels of progesterone (212.12+/-22.50 vs. 91. 99+/-15.41 ng/ml) and corticosterone (257.99+/-21.76 ng/ml vs. 31. 70+/-7.93, respectively) than saline-treated dams. No significant differences in prolactin were observed (2.36+/-0.17 vs. 2.17+/-0.19 ng rPrl132/ml). Correlation analysis indicated that there is a significant relationship between plasma levels of progesterone and corticosterone and the quality of nests built by the dams. No correlation was found within animals between prolactin plasma levels and the nest quality. Thus, cocaine's effect on progesterone and corticosterone may contribute to the series of behavioral alterations associated with cocaine exposure during pregnancy.

Animals↗

Cocaine affects progesterone plasma levels in female rats.

Female Fischer rats injected with cocaine in a "binge" pattern (15 mg/kg, IP, three times a day, at 1-h intervals) for 1 day had significantly higher levels of progesterone than saline-treated controls (p < 0.001). When analyzed by the stage of the estrous cycle, animals in proestrus showed significantly higher cocaine-induced progesterone plasma levels than those in other stages of the cycle (p < 0.01). Progesterone plasma levels were also increased after a single dose of cocaine (15 mg/kg). However, 3 h postinjection progesterone plasma levels had returned to normal. Thus, cocaine modulation of progesterone plasma levels appears to be an acute effect. In ovariectomized rats pretreated with estrogen, progesterone, or estrogen + progesterone, no significant differences were observed in progesterone plasma levels after acute "binge" pattern cocaine administration. Thus, acute cocaine induced increases in progesterone plasma levels in intact female rats are probably due to an increase in secretion rates of progesterone rather than an acceleration of its biotransformation. Due to the profound effects of progesterone in the modulation of CNS plasticity, the modulation of progesterone plasma level by cocaine may have implications for reproductive processes and neuronal functions of women. Moreover, cocaine may affect the progesterone levels in women utilizing progesterone-based contraception or steroid replacement treatment after menopause.

Animals↗

Ovarian hormone replacement affects cocaine-induced behaviors in ovariectomized female rats.

To determine whether cocaine-induced behavioral alterations are modulated by ovarian hormones, ovariectomized rats were randomly assigned to one of two drug treatment conditions: "binge" cocaine (three 15-mg/kg intraperitoneal (ip) injections, 1 h apart) or saline administration; and four hormone pretreatment sub-groups: vehicle control, estrogen, progesterone, or estrogen+progesterone. Cocaine-treated animals displayed more locomotor activity than saline-treated animals and locomotor activity was higher after the third injection than after the first two injections. When analyzed according to hormone group, the administration of estrogen+progestrone suppressed cocaine-induced locomotion after the first injection; this effect was significant when compared to estrogen-pretreated animals. While in each condition cocaine-treated animals displayed significantly higher stereotypic activity than saline-treated animals, in the estrogen+progesterone replacement group, there was more activity after the second injection of cocaine than after the first. Interestingly, animals in the estrogen+progesterone group had significantly lower plasma levels of the cocaine metabolite, benzoylecgonine, than animals in the progesterone or estrogen groups. These results extend our earlier findings in the intact female rat, which suggest an interaction between the endocrine environment, cocaine metabolism, and cocaine-induced behaviors. These effects may underlie reported sex and estrous cycle differences in cocaine-induced behavioral activity.

Animals↗

Estrous cycle differences in cocaine-induced stereotypic and locomotor behaviors in Fischer rats.

This study was conducted to characterize female behavioral response to acute 'binge' pattern cocaine administration (15 mg kg(-1) i.p., three times a day, at 1 h intervals) during the different stages of the estrous cycle in Fischer rats. Cocaine administration significantly increased stereotypic behavior and locomotion in females. Animals in estrus showed significantly higher cocaine-induced stereotypic and locomotive behavioral responses than those in other stages of the cycle. Plasma levels of the cocaine metabolite benzoylecgonine during metestrus diestrus were significantly higher than during estrus and proestrus probably reflecting more rapid biotransformation of cocaine. Therefore, it is likely that the hormonal fluctuations associated with the estrous cycle modulate both cocaine metabolism and the behavioral responses to cocaine in female rats. This in turn may have important implications in gender differences in behavioral responses to cocaine.

Animals↗

Cocaine impairs maternal nest building in pregnant rats.

The present study investigated the onset of maternal nest building in pregnant Fischer rats following chronic repeated cocaine administration. Pregnant Fischer rats were injected with saline or cocaine, 15 mg/kg, three times daily at 1-h intervals for 10 days starting on gestation day 8. Cocaine-exposed females incorporated less material into their nests and built fewer fully completed circular nests than control animals. The overall quality of the nest in cocaine exposed dams was significantly lower than that of control animals. Furthermore, cocaine exposed dams gained less weight than control females. However, no difference in number of pups, weight, or length of pups was observed between groups. Thus, it seems that cocaine disrupts the interest and skill in nest building of pregnant rats.

Animals↗

Estrogen regulation of mu-opioid receptor mRNA in the forebrain of female rats.

Previous studies have suggested that opioids play a role in the regulation of reproductive behaviors in the female rat. The present study examined whether estrogen treatment alters mu-opioid receptor mRNA levels in different areas of the forebrain of ovariectomized (OVX) female rats using the in situ hybridization technique. We observed an increase in mu-opioid receptor mRNA levels in the ventromedial nucleus of the hypothalamus (VMH) and arcuate nucleus (ARN) after 48 h of 10 microg of 17-beta-estradiol-3-benzoate treatment when compared to OVX females. No effects of estrogen were observed on mu-opioid receptor mRNA levels in the posterior medial nucleus of the amygdala (MeAmyg), hippocampus, caudate-putamen (CPu) or the medial habenula. Our result suggests that the estrogenic regulation of mu-opioid receptor in the CNS may in part be mediated by de novo synthesis and/or stability of the mu-opioid receptor message.

Animals↗

Effects of estrogen on oxytocin receptor messenger ribonucleic acid expression in the uterus, pituitary, and forebrain of the female rat.

Oxytocin receptors are regulated during parturition and lactation. Gonadal steroids are thought to be key players in this regulation. It is not well documented how oxytocin receptor gene expression is regulated in the CNS. In this study we analyzed potential estrogen effects on the oxytocin receptor mRNA levels in some areas integral to the limbic-hypothalamic system, namely the ventromedial nucleus of the hypothalamus (VMH), posterior medial nucleus of amygdala (MeAmyg), and arcuate nucleus (ARC), as well as the caudate putamen (CPu), CA1 region of the hippocampus, anterior pituitary, and uterine tissue of ovariectomized (OVX) female rats. By in situ hybridization we observed a 4.4-fold increase in oxytocin receptor mRNA levels in the VMH after 48 h of estrogen treatment when compared to OVX rats. Smaller increases were observed in the MeAmyg, hippocampus, and anterior pituitary (3.18, 1.76, and 2.55, respectively). No changes in oxytocin receptor mRNA levels were observed in the CPu or ARC after estrogen treatment. A similar finding resulted from slot-blot analysis of total mRNA extracts. In uterine tissue, 48 h of estrogen treatment increased oxytocin receptor mRNA level in the myometrium (3.13-fold). No changes in oxytocin receptor mRNA levels were observed after 12 and 24 h of estrogen treatment. These findings suggest that the estrogenic regulation of oxytocin receptor binding in both CNS and uterine tissues may in part be mediated by de novo synthesis of oxytocin receptor mRNA or by alterations in the stability of oxytocin receptor gene transcripts.

Amygdala↗

Anesthesia during hormone administration abolishes the estrogen induction of preproenkephalin mRNA in ventromedial hypothalamus of female rats.

Estrogen treatment increases preproenkephalin (PPE) mRNA levels in the ventromedial nucleus of the hypothalamus (VMH). Roy et al. (Brain Res., 337 (1985) 163-166) discovered that anesthesia during estrogen priming could reduce female rat sexual receptivity. In the present study we tested whether the action of estrogen to induce PPE gene expression in the VMH could be similarly affected by anesthesia. By quantitative in situ hybridization and slot-blot analysis techniques we found a 1.8-fold increase in PPE mRNA levels in the VMH after 1 hour of estrogen treatment in ovariectomized (OVX) Sprague-Dawley female rats. Anesthetizing the rats with pentobarbital for 1 h during the exposure to estrogen blocked the estrogen induction of PPE mRNA in the VMH. By way of contrast no changes in the PPE mRNA levels were observed in the caudate putamen. A similar trend was seen using chloral hydrate. It appears that neuronal activity is required for the early phase of estrogen induction of PPE mRNA levels in the VMH. This in turn could be correlated with changes in female sociosexual behaviors.

Anesthesia, General↗

Estrogen regulation of gonadotropin-releasing hormone receptor messenger RNA in female rat pituitary tissue.

Gonadotropin releasing hormone (GnRH) is crucial in regulating the reproductive system of female vertebrates. In the present study we have analyzed the estrogen regulation of the GnRH receptor mRNA at the cellular level in Sprague-Dawley female rats. Northern blot analysis detected 3 species (5.0, 4.5 and 1.4 kb) of GnRH receptor mRNA in pituitary tissues. The GnRH receptor mRNA levels of these 3 species were increased by estrogen. By in situ hybridization we observed a 3.5-fold increase in GnRH receptor mRNA levels after 48 h of estrogen treatment when compared to ovariectomized (OVX) rats, 12 h of estrogen treatment did not change the GnRH mRNA levels. Similar increases in GnRH receptor mRNA levels by estrogen were also found in Wistar-Imamichi female rat pituitary tissue. In situ hybridization analysis identified clusters of anterior pituitary cells that expressed the GnRH receptor mRNA. The estradiol effect depends on increased mRNA levels in these clusters. Moreover, a significant increase in the number of pituitary cells that expressed GnRH receptor was observed after 48 h of estrogen treatment. These findings suggest that the mechanisms for estrogen regulation of GnRH receptor include changing levels of GnRH receptor mRNA in the rat pituitary.

Animals↗

Estrogen regulation of preproenkephalin messenger RNA in the forebrain of female mice.

We studied the effects of 10 micrograms of 17-beta-estradiol-3-benzoate treatment on preproenkephalin (PPE) mRNA expression in female ovariectomized (OVX) Swiss Webster mice after 0, 1, 6, 12, 24, or 48 h, using the in situ hybridization technique. The VMH showed a 1.6- and 3.3-fold increase in PPE mRNA levels after 24 and 48 h of estrogen treatment (respectively) when compared to OVX females. No differences at 1, 6 or 12 h of estrogen treatment groups were observed compared to control groups. PPE mRNA levels were also increased at 24 and 48 h after estrogen treatment in the posterior medial nucleus of the amygdala (MeAmyg) by 3.3- and 2.5-fold, respectively, and in the arcuate nucleus (ARC) by 2- and 1.9-fold, respectively. No effects of estrogen were observed on PPE mRNA levels in the caudate-putamen (CPu) or the posterior lateral cortical nucleus of the amygdala (plCoAmyg). Furthermore, basal levels of PPE mRNA expression in the VMH and MeAmyg of female mice were lower than those observed in rats, although levels in the CPu, plCoAmyg, and ARC were similar between females of the two species. In conclusion, we have found two differences between the species. First, Swiss mice demonstrated a slower time course of estrogen induction of PPE mRNA in the VMH, ARC. and MeAmyg compared to female rats. Second, there are differences in basal levels of PPE in the MeAmyg and VMH.

Animals↗

An immortalized mouse neuroepithelial cell line with neuronal and glial phenotypes.

Evidence from retroviral marking techniques and immortalized cell lines indicates that multipotential stem cells exist in many areas of the developing central nervous system. However, the factors that influence the commitment of these stem cells into distinct neuronal or glial lineages are not known. We have created an immortalized hypothalamic cell line derived from embryonic day 14 hypothalamic cells with a replication-defective retroviral construct containing a temperature-sensitive allele (tsA58) of the large T antigen of the simian virus 40. The clonality of this cell line, which we have named V1, was established by single cell cloning and by Southern blot analysis. V1 cells exhibit two different morphologies: the vast majority of cells are flat and stellate, and a smaller number are phase-bright round cells with processes. V1 cells express nestin and neural-cell adhesion molecule, typical of proliferating neuroepithelial cells. They also express glial fibrillary acidic protein and S100 as well as the low molecular weight neurofilament protein. In addition, the phase-bright, process-bearing V1 cells stain intensely for many typical neuronal proteins, such as low, medium and high molecular weight neurofilament proteins, tau protein, microtubule-associated protein-2, and neuron-specific enolase. The phase-bright cells also have condensed chromatin and display mitotic spindles, indicating that they are in mitosis. When V1 cells are transferred from the permissive temperature (33 degrees C) to the restrictive temperature (39 degrees C), there is a decrease in expression of NF-L and an increase in expression of NF-H and glial fibrillary acidic protein in the flat V1 cells. The enhanced expression of neuronal antigens in mitotically active V1 cells is novel and may represent a more general property of the differentiation process. We suggest that V1 cells arise from a mixed neural/glial neuroepithelial progenitor cell that expresses both neuronal- and glial-specific proteins in the developing hypothalamus.

Animals↗

Applications of immortalized cells in basic and clinical neurology.

Immortalized cell lines can serve as model systems for studies of neuronal development and restoration of function in models of neurological disease. Cell lines which result from spontaneous or experimentally-induced tumors have been used for these purposes. More recently, the techniques of genetic engineering have resulted in the production of cell lines with specific desired characteristics. This has been accomplished by insertion of a desired gene into a pre-existing immortal cell or by immortalizing primary cells. The production of immortal cell lines using temperature-sensitive immortalizing genes offers an additional method of controlling gene expression, and thereby controlling cell proliferation and differentiation. In the nervous system, these techniques have produced immortal cell lines with neuronal and glial properties.

Cell Line↗